The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Alluzience, 200 Speywood units/mL, solution for injection

Ipsen PharmaPA1613/004/001

Main Information

Trade NameAlluzience, 200 Speywood units/mL, solution for injection
Active SubstancesBotulinum Toxin A - Haemagglutinin Complex
Dosage FormSolution for injection
Licence HolderIpsen Pharma
Licence NumberPA1613/004/001

Group Information

ATC CodeM03AX01 botulinum toxin


License statusAuthorised
Licence Issued10/09/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back